Literature DB >> 18436805

Alpha2-antiplasmin is a critical regulator of angiotensin II-mediated vascular remodeling.

Yongzhong Hou1, Kiyotaka Okada, Chikako Okamoto, Shigeru Ueshima, Osamu Matsuo.   

Abstract

OBJECTIVE: Alpha2-antiplasmin (alpha2-AP) is the major circulating inhibitor of plasmin, which plays a determining role in the regulation of intravascular fibrinolysis. We investigated the role of alpha(2)-AP on vascular remodeling in response to angiotensin II (Ang II). METHODS AND
RESULTS: alpha2-AP-deficient mice were performed. Ang II and N(omega)-nitro- L-arginine methyl ester (L-NAME)-induced perivascular fibrosis was significantly decreased in alpha2-AP-/- mice compared with wild-type mice. In situ gelatinolytic activity analysis shows that perivascular gelatinolytic activity was increased in alpha2-AP-/- mice, which was responsible for decreased perivascular fibrosis in response to Ang II and L-NAME. Ang II-induced arterial wall thickening, vascular cell proliferation, apoptosis, c-Myc, and collagen I expression were significantly decreased in alpha2-AP-/- mice compared with wild-type mice. Further analysis shows that increased p53 and p21 expression were responsible for inhibition of Ang II-induced vascular remodeling in alpha2-AP-/- mice.
CONCLUSIONS: The results show that alpha2-AP is a critical regulator for vascular remodeling by inhibiting p53/p21 pathway, suggesting that alpha2-AP is proposed to be a potential therapeutic target for vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18436805     DOI: 10.1161/ATVBAHA.108.165688

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

1.  Vasculoprotective effects of Centella asiatica, Justicia gendarussa and Imperata cylindrica decoction via the NOXs-ROS-NF-κB pathway in spontaneously hypertensive rats.

Authors:  Erna Sulistyowati; Ren-Long Jan; Shu-Fen Liou; Ying-Fu Chen; Bin-Nan Wu; Jong-Hau Hsu; Jwu-Lai Yeh
Journal:  J Tradit Complement Med       Date:  2019-06-24

2.  α2AP regulates vascular alteration by inhibiting VEGF signaling in systemic sclerosis: the roles of α2AP in vascular dysfunction in systemic sclerosis.

Authors:  Yosuke Kanno; En Shu; Hiroyuki Kanoh; Ayaka Matsuda; Mariko Seishima
Journal:  Arthritis Res Ther       Date:  2017-02-03       Impact factor: 5.156

3.  Alternatively activated macrophages are associated with the α2AP production that occurs with the development of dermal fibrosis : The role of alternatively activated macrophages on the development of fibrosis.

Authors:  Yosuke Kanno; En Shu; Hirofumi Niwa; Hiroyuki Kanoh; Mariko Seishima
Journal:  Arthritis Res Ther       Date:  2020-04-10       Impact factor: 5.156

4.  Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease.

Authors:  Satish Singh; Sofiyan Saleem; Guy L Reed
Journal:  Front Cardiovasc Med       Date:  2020-12-23

5.  Luteolin Ameliorates Hypertensive Vascular Remodeling through Inhibiting the Proliferation and Migration of Vascular Smooth Muscle Cells.

Authors:  Jie Su; Han-Ting Xu; Jing-Jing Yu; Jian-Li Gao; Jing Lei; Qiao-Shan Yin; Bo Li; Min-Xia Pang; Min-Xia Su; Wen-Jia Mi; Su-Hong Chen; Gui-Yuan Lv
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-30       Impact factor: 2.629

Review 6.  The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis.

Authors:  Yosuke Kanno
Journal:  Int J Mol Sci       Date:  2019-01-31       Impact factor: 5.923

7.  Early Pregnancy Exposure to Ambient Air Pollution among Late-Onset Preeclamptic Cases Is Associated with Placental DNA Hypomethylation of Specific Genes and Slower Placental Maturation.

Authors:  Karin Engström; Yumjirmaa Mandakh; Lana Garmire; Zahra Masoumi; Christina Isaxon; Ebba Malmqvist; Lena Erlandsson; Stefan R Hansson
Journal:  Toxics       Date:  2021-12-06

Review 8.  α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Authors:  Yosuke Kanno; En Shu
Journal:  Life (Basel)       Date:  2022-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.